- RECOMBITEK Parvo vaccine provides a 36-month duration of immunity (serologic). In placebo-controlled studies, 100% of vaccinated puppies were protected against CPV-2a, 2b, and 2c challenges.
- Safe for puppies as young as 6 weeks of age.1
- High-titer, low-passage profile.
- Proven effective in the presence of maternal antibodies.2
RECOMBITEK® Canine Parvo (CPV)
RECOMBITEK® Canine Parvo vaccine contains canine parvovirus, propagated in a stable cell line. Safety and efficacy of this product have been demonstrated by vaccination and challenge tests.
This product has been shown to be effective for the vaccination of healthy dogs, 6 weeks of age and older, against canine parvovirus. The duration of immunity has not been determined.1
Aseptically administer 1 mL (1 dose) subcutaneously or intramuscularly into healthy dogs. For primary vaccination, revaccinate with a second 1-mL dose 2 to 3 weeks later. The presence of maternal antibodies is known to interfere with the development of active immunity in dogs and additional boosters will be required in most young animals.
Precautions: Contains gentamicin and thimerosal as preservatives. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine, as directed by a veterinarian. This product has not been tested in pregnant animals. In case of human exposure, contact a physician. Inactivate unused contents before disposal.
Store at 35-46ºF (2-8ºC). Do not freeze. Do not use chemicals to sterilize syringes and needles.
Do not mix with other products.
For use in animals only. Sold to veterinarians only.
Benefits of RECOMBITEK Canine Parvo Vaccine
In a laboratory study, puppies were vaccinated at 8, 10, and 12 weeks with RECOMBITEK Parvo vaccine or placebo and challenged oronasally at 14 weeks of age with virulent CPV-2a and CPV-2b. Nine days after challenge, vaccinated puppies were bright and alert, and none of them developed leukopenia. In contrast, 80% of unvaccinated puppies developed clinical signs of parvovirus infection, 40% developed leukopenia, and 30% died. Results showed 100% of vaccinated puppies were protected against bivalent CPV-2a and CPV-2b after challenge in this study.
After 14 days following a single dose of the RECOMBITEK Parvo vaccine, dogs were challenged oronasally with CPV-2c. All vaccinated dogs sero-converted after a single dose. Clinical signs were observed, and white blood cell counts, and serology were performed up to day 28 following vaccination. No clinical signs were observed in vaccinated puppies, whereas 100% of the controls had one or more clinical signs of parvovirus infection. Additionally, there was significant alleviation of leukopenia in vaccinated puppies compared to controls.
On day 9 post challenge, 100% of the vaccinated puppies were bright, alert, and responsive, and none had developed leukopenia, compared with 40% of controls.2
Log in to BI-CONNECT™ to place an order for RECOMBITEK Canine Parvo.
RECOMBITEK® Canine Vaccines
RECOMBITEK® vaccines are highly purified, making them a safe and effective option to help protect your canine patients from dangerous diseases.
IMRAB® Rabies Vaccines
Veterinarians worldwide trust US market-leading IMRAB® vaccines for proven multi-species rabies protection.4
PUREVAX® Feline Vaccines
Adjuvants can present potential risks to feline patients.5,6,7 PUREVAX® feline vaccines have been designed to elicit a protective immune response without the addition of adjuvants.
- RECOMBITEK® Canine Parvo Product Label.
- Data on file at Boehringer Ingelheim.
- Brunet S, Toulemonde C, Cariou C. Efficacy of vaccination with a canine parvovirus type 2 against a virulent challenge with a CPV type 2c (glu426). Merial S.A.S, 254 rue Marcel M rieux, 69007, Lyon, France.
- Data on file at Boehringer Ingelheim.
- Greene CE, Schultz RD. Immunoprophylaxis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St Louis, MO: Elsevier Saunders; 2012:1166-1169.
- McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463-472.
- Day MJ, Schoon H-A, Magnol J-P, et al. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine. 2007; 25:4073-4084.
RECOMBITEK® and IMRAB® are registered trademarks and BI-CONNECT™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. PUREVAX® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.